Ensor CR, Iasella CJ, Harrigan (Zhang) KM, Morrell MR, Moore CA, Shigemura N, Zeevi A, McDyer JF, Venkataramanan R. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant. 2018 Jun;18(6):1527-33. doi: 10.1111/ajt.14723
Coffin D, Duval K, Martel S, Granton J, Lefebvre MC, Meads DM, Twiss J, McKenna SP. Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Can Respir J. 2008 Mar;15(2):77-83.
Chen XH, Rodríguez S, Hawe E, Talmud PJ, Miller GJ, Underhill P, Humphries SE, Day IN. Evidence of admixture from haplotyping in an epidemiological study of UK Caucasian males: implications for association analyses. Hum Hered. 2004;57(3):142-55.
Rivero E, Varas-Lorenzo C, Maguire AR, Eisen HJ, Pedersen TR, Nashan B, Elkammas E. 10-Year predicted probability of coronary heart disease in renal transplant recipients treated with everolimus or mmf. Poster presented at the American Transplant Congress; April 2002. Washington, DC. [abstract] Am J Transplant. 2002; 2(Suppl 3):418.